Statement on Glucagen Hypokit supply 2 August 2023 Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. The Glucagen Hypokit is used to treat severe hypoglycaemia where a person is unconscious or unable to take oral hypo treatments. If a person has a severe hypo and you don’t have a Hypokit you need to call 000 immediately. Diabetes Australia is working with the diabetes sector and the TGA to ensure people at highest risk are prioritized access to available supply. The TGA have also activated Section 19A provisions and is arranging imports of Hypokits from other countries. If you have concerns please talk to someone from your diabetes healthcare team.
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading
News 3 July 2026 Daonil to be discontinued in Australia People living with type 2 diabetes who use Daonil are encouraged to speak with their doctor or diabetes healthcare team... Continue Reading
